About US
Contact us
-
ASH: Gilead Sciences touts 'astounding' Yescarta survival results at 3 yearsORLANDO, FLORIDA—How long can a single infusion of Gilead Sciences CAR-T drug Yescarta continue helpingpatients with refractory large B-cell lymphoma? Pretty long, the companyshowed Saturday. Among p2019/12/9
-
Gilead, seeking HIV patent extension, faces 'gamesmanship' claims from patient groupGilead has faced criticism and lawsuits over its development timeline forHIV medicines, and the topic resurfaced this week as advocates challenged the company’s effort to scorepatent extensions. In a2019/12/6
-
FiercePharmaAsia—Astellas' $3B gene therapy bet; China's PD-1 coverage; Hanmi-Rapt I-O dealDue to the Thanksgiving holiday, we're bringing you two weeks of biopharma movement in this issue. Astellas is marching into gene therapy with a $3 billion buyout of Audentes Therapeutics. Only one P2019/12/6
-
Novartis' Sandoz, not 'ashamed' of generics focus, is aiming for Teva's top spot: CEOSeveral major generics players have been shifting focus onto innovative medicines, but don’t expect that from Sandoz, the Novartis subsidiary’s newly minted CEO said. In fact, it is coming after Teva2019/12/5
-
Gilead, HHS kick off program to provide PrEP drugs Truvada, Descovy for freeGilead and the U.S. Department ofHealth and Human Services(HHS) are locked in a patent dispute over HIV prevention meds, but as the fight plays out, they’re also partners in anew programto provide th2019/12/5
-
DOJ inks price fixing settlement with small generics player. Will others follow?Top generics players have faced years of price-fixing heat, and now federal prosecutors have inked another settlement with a small company. The upshot? Prosecutors have another firm cooperating in th2019/12/4
-
Amgen snags another Enbrel outcomes-based payment deal as it seeks to prop up aging blockbusterWhen Amgen signed an outcomes-based reimbursement deal for its blockbuster rheumatoid arthritis drug Enbrel with Harvard Pilgrim Healthcare in 2017, it seemed like a strategy for preserving the marke2019/12/4
-
Pelosi pricing plan will yield 100 fewer new drugs, White House predictsAs debate over drug pricing proposals rolls on in Washington, White House advisers have concludedHouse Speaker Nancy Pelosi's aggressive pricing plan would result in 100 fewer new drugs over a decade2019/12/3
-
Merck, insurers fight over $1.3B in damages from cyberattack: BloombergWhen Merck first confirmed a cyberattack hit the company back in June 2017, it was impossible to know the extent of the damage or what would come from the attack. But those details are a little clear2019/12/3
-
AstraZeneca offloads more Seroquel rights, this time to Cheplapharm for $42MAstraZeneca has been hiving off drug rights left and right in recent years as a quick—but controversial—way to generate cash. With billions in rights sales already in its pocket, the company Tuesdayo2019/12/2